Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:PHAR NASDAQ:SLRN NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$88.03+2.9%$51.77$4.77▼$92.91$6.65B0.591.09 million shs3.20 million shsPHARPharming Group$15.13+1.7%$11.69$6.73▼$17.08$1.05B0.0511,672 shs21,422 shsSLRNAcelyrin$2.27$2.27$1.85▼$7.10$229.17M1.071.29 million shsN/AZYMEZymeworks$15.05+6.9%$13.63$9.03▼$17.70$1.13B1.27528,693 shs627,107 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+8.64%+25.72%+974.85%+618.03%PHARPharming Group0.00%+1.95%+24.53%+26.71%+102.82%SLRNAcelyrin0.00%0.00%0.00%0.00%-49.22%ZYMEZymeworks0.00%+1.62%+23.77%+19.44%+29.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$88.03+2.9%$51.77$4.77▼$92.91$6.65B0.591.09 million shs3.20 million shsPHARPharming Group$15.13+1.7%$11.69$6.73▼$17.08$1.05B0.0511,672 shs21,422 shsSLRNAcelyrin$2.27$2.27$1.85▼$7.10$229.17M1.071.29 million shsN/AZYMEZymeworks$15.05+6.9%$13.63$9.03▼$17.70$1.13B1.27528,693 shs627,107 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+8.64%+25.72%+974.85%+618.03%PHARPharming Group0.00%+1.95%+24.53%+26.71%+102.82%SLRNAcelyrin0.00%0.00%0.00%0.00%-49.22%ZYMEZymeworks0.00%+1.62%+23.77%+19.44%+29.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.334.89% UpsidePHARPharming Group 3.00Buy$30.0098.28% UpsideSLRNAcelyrin 2.33Hold$7.33223.05% UpsideZYMEZymeworks 2.90Moderate Buy$21.4342.38% UpsideCurrent Analyst Ratings BreakdownLatest ABVX, ZYME, PHAR, and SLRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$70.00 ➝ $112.007/23/2025ABVXAbivaxLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$74.007/23/2025ABVXAbivaxLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $101.007/23/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $70.007/23/2025ABVXAbivaxGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $101.007/23/2025ABVXAbivaxMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$71.007/23/2025ABVXAbivaxJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$33.00 ➝ $95.007/18/2025ABVXAbivaxJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.007/18/2025ABVXAbivaxCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform7/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$13.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/APHARPharming Group$297.20M3.49$0.07 per share205.86$3.25 per share4.66SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/AZYMEZymeworks$122.87M9.21N/AN/A$6.63 per share2.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/APHARPharming Group-$11.84M-$0.13N/A504.33N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%N/AZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest ABVX, ZYME, PHAR, and SLRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25PHARPharming Group0.382.792.07SLRNAcelyrinN/A7.157.15ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%PHARPharming Group0.03%SLRNAcelyrin87.31%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/APHARPharming Group2.07%SLRNAcelyrin13.60%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionablePHARPharming Group28068.51 million67.10 millionNot OptionableSLRNAcelyrin135100.95 million86.68 millionOptionableZYMEZymeworks46075.17 million67.56 millionOptionableABVX, ZYME, PHAR, and SLRN HeadlinesRecent News About These CompaniesBrokers Set Expectations for Zymeworks FY2025 EarningsSeptember 7 at 6:51 AM | marketbeat.comEcoR1 Capital LLC Purchases 2,231,469 Shares of Zymeworks Inc. $ZYMESeptember 6 at 8:27 AM | marketbeat.comTrexquant Investment LP Has $2.63 Million Stake in Zymeworks Inc. $ZYMESeptember 6 at 4:43 AM | marketbeat.comBloom Burton Comments on Zymeworks FY2025 EarningsSeptember 6 at 2:27 AM | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 5 at 2:45 AM | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - What's Next?September 4 at 1:23 PM | marketbeat.comADAR1 Capital Management LLC Acquires New Position in Zymeworks Inc. $ZYMESeptember 4 at 7:41 AM | marketbeat.comZymeworks Inc. $ZYME Stake Reduced by Redmile Group LLCSeptember 4 at 7:28 AM | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LPSeptember 4 at 7:17 AM | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFZymeworks halts development of cancer drug after trial setbackSeptember 2, 2025 | reuters.comZymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell EngagerSeptember 2, 2025 | globenewswire.comWellington Management Group LLP Reduces Stock Holdings in Zymeworks Inc. $ZYMESeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 198,812 Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comVanguard Group Inc. Decreases Stock Position in Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Zymeworks Inc. $ZYMEAugust 31, 2025 | marketbeat.comWalleye Capital LLC Has $2.95 Million Stake in Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comAlphaQuest LLC Purchases 28,868 Shares of Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comZymeworks Reports Q2 Results and FDA ClearanceAugust 19, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025ABVX, ZYME, PHAR, and SLRN Company DescriptionsAbivax NASDAQ:ABVX$88.03 +2.48 (+2.90%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$87.69 -0.34 (-0.39%) As of 09/5/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Pharming Group NASDAQ:PHAR$15.13 +0.26 (+1.75%) Closing price 09/5/2025 03:58 PM EasternExtended Trading$15.13 0.00 (0.00%) As of 09/5/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Acelyrin NASDAQ:SLRNAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Zymeworks NYSE:ZYME$15.05 +0.97 (+6.89%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.18 +0.13 (+0.83%) As of 09/5/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
